drugset / Trial / NCT04386980

Study to Evaluate Resiniferatoxin in Patients With Knee Osteoarthritis Whose Total Knee Replacement Surgery is Delayed

NCT04386980

Phase 3 Withdrawn Sorrento Therapeutics, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

Efficacy and safety study of resiniferatoxin versus placebo to manage pain in patients with knee osteoarthritis whose TKR surgery is delayed

Timeline

Start
2021-04
Primary completion
2022-06
Completion
2022-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Resiniferatoxin Other / unclassified 12.5 ug Other

Indications